Related Experiment Video
Updated: Aug 15, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
Allelic isoforms and decrease in serotonin transporter mRNA in lymphocytes of patients with major depression
1Laboratorio de Neuroquímica, Centro de Biofísica y Bioquímica, Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela.
Abstract:
Serotonin transporter, measured by the specific binding of [(3)H]paroxetine, has been reported to be reduced in circulating lymphocytes of patients with major depression. Due to this observation, the objective of the present report was to determine the levels of serotonin transporter mRNA in lymphocytes obtained from 29 major depression patients (4 men, age 33.10+/-1.63 years) and from 30 subjects included as a control group (4 men, age 37.54+/-2.18 years) using RT-PCR. The patients were diagnosed according to the criteria of the American Psychiatric Association, and had a severity of depression of 32.68+/-1.55 determined by the Hamilton Rating Scale for Depression. The DNA was submitted to polymerase chain reaction with primers for the 5' regulatory region of human serotonin transporter, which could show the long and the short allelic forms of the transporter gene for the 5 HTTLPR polymorphism. Semiquantitative analysis was performed using beta-actin as internal and external standard. Control subjects presented the two allelic forms in 9.09% and depressed patients in 8.69%. The long variant was present in 73% of controls and in 60% of patients, without significant differences. There was a significant reduction in mRNA in depressed patients expressing the long allele. The number of immunofluorescent lymphocytes, labeled with a specific antibody against serotonin transporter, was reduced in the patients, as well as CD3+ lymphocytes. Serotonin and 5-hydroxyindoleacetic acid in platelet-poor plasma or lymphocytes did not differ between depressed patients and controls. The reduction in lymphocyte serotonin transporter described in major depression might be due to a decrease in the level of its mRNA and in the number of cells expressing it. These observations might implicate that functional modifications are associated with nervous-immune interactions in depression.
Insights
Major depression is linked to reduced serotonin transporter mRNA and fewer cells expressing it in lymphocytes. This suggests nervous-immune interactions may play a role in depression.
Area of Science:
- Neuroscience
- Immunology
- Genetics
Background:
- Reduced serotonin transporter (SERT) binding in lymphocytes is observed in major depression.
- SERT plays a crucial role in regulating serotonin levels, impacting mood and behavior.
Purpose of the Study:
- To investigate serotonin transporter mRNA levels in lymphocytes of major depression patients.
- To explore the association between SERT gene polymorphism (5-HTTLPR) and mRNA levels in depression.
Main Methods:
- RT-PCR was used to quantify serotonin transporter mRNA in lymphocytes from 29 major depression patients and 30 controls.
- 5-HTTLPR polymorphism analysis was performed.
- Immunofluorescence and cell counting (CD3+) were utilized to assess lymphocyte populations.
Main Results:
- Depressed patients showed significantly reduced serotonin transporter mRNA levels, particularly those expressing the long allele of the 5-HTTLPR gene.
- The number of immunofluorescent lymphocytes and CD3+ lymphocytes was lower in patients with major depression.
- No significant differences were found in serotonin or 5-HIAA levels between groups.
Conclusions:
- The reduction in lymphocyte serotonin transporter in major depression may stem from decreased mRNA levels and fewer expressing cells.
- These findings suggest a potential link between nervous-immune system interactions and the pathophysiology of depression.
Related Concept Videos
G-protein Coupled Receptors
Depression: Overview
RNA Splicing
Long-term Depression
Long-term Depression
Calcium Ion Concentration Mechanism
If over time, all...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase